Clinical Research Directory
Browse clinical research sites, groups, and studies.
Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer
Sponsor: Fudan University
Summary
Fruquintinib, as a standard treatment for refractory metastatic colorectal cancer (mCRC), has attracted increasing research efforts to explore its innovative strategies in combination with immunotherapy and chemotherapy because of its multi-target mechanism which enhances the sensitivity of the immune system and chemotherapy, aiming to further improve the survival benefits for mCRC patients. Trifluridine/tipiracil (TAS-102) is also a standard treatment for mCRC. This study aims to investigate the safety and effectiveness of the combined use of these two drugs in mCRC.
Official title: A Single-center, Prospective Cohort Study of Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
OBSERVATIONAL
Enrollment
0
Start Date
2020-01-01
Completion Date
2024-05-31
Last Updated
2026-08-03
Healthy Volunteers
No
Interventions
Fruquintinib Combined With TAS-102
Fruquintinib Combined With TAS-102
Locations (1)
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China